Registration is now closed.
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
US-Guided Percutaneous Thermal Ablation for Papillary Thyroid Microcarcinoma: A Pilot Study
- Presentation Speakers / Moderators
Aim to prospectively evaluate the safety and efficacy of thermal ablation for treating low-risk unifocal Papillary Thyroid Microcarcinoma (PTMC). The patients with unifocal PTMC nodule were enrolled in this study. Thermal ablation for PTMC was performed and contrast-enhanced ultrasound (CEUS) was used to estimate the extent of ablation immediately after thermal ablation. Complications were recorded. The size, volume of the ablation area and thyroid hormones were measured, and clinical evaluations were performed at 1, 3, 6 ,12 and 18months. From July 2016 to July 2017,The prospective study was conducted in 107 patients. The procedures of thermal ablation were well tolerated without serious complications. Compared with the volume immediately after thermal ablation, the mean Volume Reduction Ratio (VRR) of ablated lesion was 0.457±0.218 (range 0.040–0.979), 0.837±0.150 (range 0.259–1), 0.943±0.090 (range 0.491–1), 0.994–0.012 (range 0.938–1), and 0.999±0.002 (range 0.992–1) at 1, 3, 6, 12, and 18 months after thermal ablation, respectively. Significant differences in the VRR were found between every two follow-up times(P<0.01). Before and 1 month after thermal ablation, results of the thyroid function were normal in all patients and there were no significant diffidence(p>0.05). No regrowth of treated tumours, local recurrence or distant metastases were detected during follow up. Thermal ablation showed a short- term safe and effective strategy for treating low-risk small PTMCs and might represent an potential alternative for the patients with PTMC.
Two Approaches to Level 5 Neck Dissection
- Jeff Blumberg